Drug intelligence / Profile preview

Phesgo + Abraxane + inavolisib

Development stage: Unknown
Lead developer: Roche
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous, Intravenous, Oral

Overview

This combination therapy is a neoadjuvant regimen being investigated for the treatment of PIK3CA-mutated, HER2-positive early breast cancer. It consists of **Phesgo** (a fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection), **Abraxane** (nab-paclitaxel; nanoparticle albumin-bound paclitaxel), and **inavolisib** (GDC-0077), an investigational, oral, highly selective PI3Kα inhibitor. The regimen aims to overcome resistance to anti-HER2 therapy mediated by PIK3CA mutations by simultaneously blocking HER2 signaling and the downstream PI3K pathway, while providing cytotoxic chemotherapy. This specific combination is currently being evaluated in a Phase 2 clinical trial (NCT05300334) led by Dr. Zhimin Shao at Fudan University.

Other names: pertuzumab + trastuzumab + hyaluronidase + nab-paclitaxel + inavolisibPH-FDC SC + nab-paclitaxel + inavolisib

Targets

PIK3CA (Phosphoinositide 3-kinase alpha)TUBB (Tubulin (alpha and beta subunits))ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on Phesgo + Abraxane + inavolisib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phesgo + Abraxane + inavolisib.

Explore the full profile